Case of chilblain lupus triggered by adalimumab therapy in a patient with psoriasis

2021 ◽  
Author(s):  
Yavuz Semiz ◽  
Esra Yıldırım Bay ◽  
İlteriş Oğuz Topal ◽  
Özben Yalçın
Keyword(s):  
Adalimumab Therapy ◽  
Chilblain Lupus

Chilblain Lupus Associated with Rheumatoid Arthritis

1974 ◽  
Vol 36 (3) ◽  
pp. 353-355
Author(s):  
Hiroko TSUNAWAKI ◽  
Takao SARUTA ◽  
Hideto KIMURA
Keyword(s):  
Rheumatoid Arthritis ◽  
Chilblain Lupus

Tofacitinib for refractory chilblain lupus erythematosus

2021 ◽  
Author(s):  
Scott A. Elman ◽  
Daniel R. Mazori ◽  
Joseph F. Merola
Keyword(s):  
Lupus Erythematosus ◽  
Chilblain Lupus

scholarly journals Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

2021 ◽  
Author(s):  
Shinichiro Shinzaki ◽  
Katsuyoshi Matsuoka ◽  
Hiroki Tanaka ◽  
Fuminao Takeshima ◽  
Shingo Kato ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Fecal Calprotectin ◽  
Potential Biomarker ◽  
Adalimumab Therapy ◽  
Adalimumab Treatment ◽  
Inflammatory Bowel

Abstract Background This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD). Methods Patients with moderate-to-severe IBD initiated on adalimumab therapy were enrolled herein. Serum LRG, C-reactive protein (CRP), and fecal calprotectin (fCal) levels were measured at week 0, 12, 24, and 52. Colonoscopy was performed at week 0, 12, and 52 for ulcerative colitis (UC), and at week 0, 24, and 52 for Crohn’s disease (CD). Endoscopic activity was assessed using the Simple Endoscopic Score for Crohn’s Disease (SES-CD) for CD and the Mayo endoscopic subscore (MES) for UC. Results A total of 81 patients was enrolled. Serum LRG levels decreased along with improvements in clinical and endoscopic outcomes upon adalimumab treatment (27.4 ± 12.6 μg/ml at week 0, 15.5 ± 7.7 μg/ml at week 12, 15.7 ± 9.6 μg/ml at week 24, and 14.5 ± 6.8 μg/ml at week 52), being correlated with endoscopic activity at each time point (SES-CD: r = 0.391 at week 0, r = 0.563 at week 24, r = 0.697 at week 52; MES: r = 0.534 at week 0, r = 0.429 at week 12, r = 0.335 at week 52). Endoscopic activity better correlated with LRG compared to CRP and fCal on pooled analysis at all time points (SES-CD: LRG: r = 0.636, CRP: r = 0.402, fCal: r = 0.435; MES: LRG: r = 0.568, CRP: 0.389, fCal: r = 0.426). Conclusions Serum LRG is a useful biomarker of endoscopic activity both in CD and UC during the adalimumab treatment.

Seven Years-Experience of adalimumab therapy for hidradenitis suppurativa in a real-life dermatologic setting

2021 ◽  
pp. 1-10
Author(s):  
G. Odorici ◽  
L. Pacetti ◽  
R. Forconi ◽  
N. Schettini ◽  
P. Zedde ◽  
...  
Keyword(s):  
Hidradenitis Suppurativa ◽  
Real Life ◽  
Adalimumab Therapy

scholarly journals P048 HISTORY OF CYTOMEGALOVIRUS COLITIS IS ASSOCIATED WITH POOR LONG-TERM OUTCOMES IN ADALIMUMAB THERAPY IN KOREAN PATIENTS WITH ULCERATIVE COLITIS: A HOSPITAL-BASED COHORT STUDY

2018 ◽  
Vol 24 (suppl_1) ◽  
pp. S17-S17
Author(s):  
Eun Hye Oh ◽  
Eun Mi Song ◽  
Sun-Ho Lee ◽  
Kiju Chang ◽  
Sung Wook Hwang ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Cohort Study ◽  
Long Term Outcomes ◽  
Korean Patients ◽  
Cytomegalovirus Colitis ◽  
Adalimumab Therapy ◽  
History Of

PWE-038 Adalimumab therapy for infliximab failures in Crohn's disease. A single-centre UK experience

Gut ◽  
2010 ◽  
Vol 59 (Suppl 1) ◽  
pp. A99.3-A100
Author(s):  
M B Sprakes ◽  
A C Ford ◽  
L Warren ◽  
D Greer ◽  
C F Donnellan ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Single Centre ◽  
Adalimumab Therapy

scholarly journals Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial

2011 ◽  
Vol 25 (8) ◽  
pp. 419-425 ◽  
Author(s):  
Remo Panaccione ◽  
Edward V Loftus ◽  
David Binion ◽  
Kevin McHugh ◽  
Shamsul Alam ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Patient Reported Outcomes ◽  
Activity Index ◽  
Work Productivity ◽  
Clinical Effectiveness ◽  
Open Label ◽  
Adalimumab Therapy ◽  
Patient Reported ◽  
Fistula Healing

OBJECTIVE: To evaluate open-label adalimumab therapy for clinical effectiveness, fistula healing, patient-reported outcomes and safety in Canadian patients with moderate to severe Crohn’s disease (CD) who were either naive to or previously exposed to antitumour necrosis factor (anti-TNF) therapy.METHODS: Patients with moderate to severe CD (CD activity index [CDAI] score of greater than 220, or Harvey-Bradshaw index [HBI] of 7 or greater) were eligible. Patients received open-label adalimumab as induction (160 mg and 80 mg subcutaneously [sc]) at weeks 0 and 2, respectively and maintenance (40 mg sc every other week) therapy. At or after eight weeks, patients with flare or nonresponse could have their dosage increased to 40 mg sc weekly. Patients were followed for a minimum of six months or until adalimumab was commercially available in Canada.RESULTS: Of the 304 patients enrolled, 160 were infliximab experienced, while 144 were anti-TNF naive. HBI remission (HBI score of 4 or lower) at week 24 was achieved by 53% of anti-TNF-naive and 36% of infliximab-experienced patients (P<0.01; P<0.001 for both groups for all visits versus baseline). Fistula healing rates at week 12 were 48% for anti-TNF-naive patients, and 26% for infliximab-experienced patients. At week 24, fistula healing rates were significantly greater for the anti-TNF-naive group (60% versus 28%; P<0.01). Improvements in quality of life and work productivity were sustained from week 4 to week 24 for all patients. Serious infections occurred in 2% of patients.CONCLUSIONS: Adalimumab therapy induced and sustained steroid-free remission in both infliximab-experienced and anti-TNF-naive patients with moderate to severe CD. Clinically meaningful rates of fistula healing were also observed. Improvements in patient-reported outcomes were sustained throughout the 24-week study period.

Adalimumab Therapy for Refractory Uveitis: A Pilot Study

2008 ◽  
Vol 24 (6) ◽  
pp. 613-614 ◽  
Author(s):  
José Luis Callejas-Rubio ◽  
Daniel Sánchez-Cano ◽  
José Luis García Serrano ◽  
Norberto Ortego-Centeno
Keyword(s):  
Pilot Study ◽  
Adalimumab Therapy
Sign in / Sign up

Export Citation Format

Share Document